Abstract:Memantine is a moderate affinity uncompetitive antagonist of glutamate NMDA receptors. It is licensed for use in moderate and severe Alzheimer's disease (AD); in the USA, it is also widely used off‐label for mild AD. To determine efficacy and safety of memantine for people with dementia. To assess whether memantine adds benefit for people already taking cholinesterase inhibitors (ChEIs). We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group's register of trials (http://www.medicine.ox.ac.uk/alois/) up to 25 March 2018. We examined clinical trials registries, press releases and posters of memantine manufacturers; and the web sites of the FDA, EMEA and NICE. We contacted authors and companies for missing information. Double‐blind, parallel group, placebo‐controlled, randomised trials of memantine in people with dementia. We pooled and analysed data from four clinical domains across different aetiologies and severities of dementia and for AD with agitation. We assessed the impact of study duration, severity and concomitant use of ChEIs. Consequently, we restricted analyses to the licensed dose (20 mg/day or 28 mg extended release) and data at six to seven months duration of follow‐up, and analysed separately results for mild and moderate‐to‐severe AD. We transformed results for efficacy outcomes into the difference in points on particular outcome scales. Across all types of dementia, data were available from almost 10,000 participants in 44 included trials, most of which were at low or unclear risk of bias. For nearly half the studies, relevant data were obtained from unpublished sources. The majority of trials (29 in 7885 participants) were conducted in people with AD. 1. Moderate‐to‐severe AD (with or without concomitant ChEIs). High‐certainty evidence from up to 14 studies in around 3700 participants consistently shows a small clinical benefit for memantine versus placebo: clinical global rating (CGR): 0.21 CIBIC+ points (95% confidence interval (CI) 0.14 to 0.30); cognitive function (CF): 3.11 Severe Impairment Battery (SIB) points (95% CI 2.42 to 3.92); performance on activities of daily living (ADL): 1.09 ADL19 points (95% CI 0.62 to 1.64); and behaviour and mood (BM): 1.84 Neuropsychiatric Inventory (NPI) points (95% CI 1.05 to 2.76). There may be no difference in the number of people discontinuing memantine compared to placebo: risk ratio (RR) 0.93 (95% CI 0.83 to 1.04) corresponding to 13 fewer people per 1000 (95% CI 31 fewer to 7 more). Although there is moderate‐certainty evidence that fewer people taking memantine experience agitation as an adverse event: RR 0.81 (95% CI 0.66 to 0.99) (25 fewer people per 1000, 95% CI 1 to 44 fewer), there is also moderate‐certainty evidence, from three additional studies, suggesting that memantine is not beneficial as a treatment for agitation (e.g. Cohen Mansfield Agitation Inventory: clinical benefit of 0.50 CMAI points, 95% CI ‐3.71 to 4.71) . The presence of concomitant ChEI does not impact on the difference between memantine and placebo, with the possible exceptions of the BM outcome (larger effect in people taking ChEIs) and the CF outcome (smaller effect). 2. Mild AD (Mini Mental State Examination (MMSE) 20 to 23): mainly moderate‐certainty evidence based on post‐hoc subgroups from up to four studies in around 600 participants suggests there is probably no difference between memantine and placebo for CF: 0.21 ADAS‐Cog points (95% CI ‐0.95 to 1.38); performance on ADL: ‐0.07 ADL 23 points (95% CI ‐1.80 to 1.66); and BM: ‐0.29 NPI points (95% CI ‐2.16 to 1.58). There is less certainty in the CGR evidence, which also suggests there may be no difference: 0.09 CIBIC+ points (95% CI ‐0.12 to 0.30). Memantine (compared with placebo) may increase the numbers of people discontinuing treatment because of adverse events (RR 2.12, 95% CI 1.03 to 4.39). 3. Mild‐to‐moderate vascular dementia. Moderate‐ and low‐certainty evidence from two studies in around 750 participants indicates there is probably a small clinical benefit for CF: 2.15 ADAS‐Cog points (95% CI 1.05 to 3.25); there may be a small clinical benefit for BM: 0.47 NOSGER disturbing behaviour points (95% CI 0.07 to 0.87); there is probably no difference in CGR: 0.03 CIBIC+ points (95% CI ‐0.28 to 0.34); and there may be no difference in ADL: 0.11 NOSGER II self‐care subscale points (95% CI ‐0.35 to 0.54) or in the numbers of people discontinuing treatment: RR 1.05 (95% CI 0.83 to 1.34). There is limited, mainly low‐ or very low‐certainty efficacy evidence for other types of dementia (Parkinson's disease and dementia Lewy bodies (for which CGR may show a small clinical benefit; four studies in 319 people); frontotemporal dementia (two studies in 133 people); and AIDS‐related Dementia Complex (one study in 140 people)). There is high‐certainty evidence showing no difference between memantine and placebo in the proportion expe -Abstract Truncated-

Memantine in the Treatment of Executive Function Deficits in Adults With ADHD

P4‐305: Withdrawn

A pilot open label prospective study of memantine monotherapy in adults with ADHD

Memantine Treatment in Alzheimer Disease: a Randomized Double-Blind Controlled Trial

Effects of Memantine on Clinical Ratings, Fluorodeoxyglucose Positron Emission Tomography Measurements, and Cerebrospinal Fluid Assays in Patients with Moderate to Severe Alzheimer Dementia A 24-Week, Randomized, Clinical Trial

A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil

Memantine for dementia.

Multicenter Research on Efficacy and Tolerance of Memantine in Chinese Patients with Alzheimer's Disease

Changes of biological markers and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24-week double-blind, randomized, placebo-controlled study

Comparative Study Of Oros-Mph And Atomoxetine On Executive Function Improvement In Adhd: A Randomized Controlled Trial

Multicenter Controlled Randomized Clinical Trial of Akatinol Memantine for Treatment of Aizheimer's Disease

N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.

[Mémantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease]

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials

A 40‐week phase 2B randomized, multicenter, double‐blind, placebo‐controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis

A Single-Blind, Placebo Controlled Trial of Triple Beaded Mixed Amphetamine Salts in DSM-5 Adults With ADHD Assessing Effects Throughout the Day

Enhancing spatial memory and pattern separation: Long-term effects of stimulant treatment in individuals with ADHD

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease

A Dopamine D1 Agonist Versus Methylphenidate in Modulating Prefrontal Cortical Working Memory

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder